LNAI Earnings — Lunai Bioworks Inc. Common Stock Post-ER Performance | BigEarnings
LNAI — Lunai Bioworks Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$3.08
Market Cap$14.0M
P/E—
52W Range$1.21 – $13.28
Next Earnings2026-09-28
About Lunai Bioworks Inc. Common Stock
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
